My Top 3 Stocks to Buy in May

The article highlights TransMedics as a buy after a steep sell-off despite Q1 2026 adjusted EPS of $0.30 versus $0.61 consensus, citing 21% revenue growth, Europe expansion, and a kidney OCS program as long-term catalysts. Rhythm Pharmaceuticals gets a constructive view ahead of FDA/European approvals already won for Imcivree in acquired hypothalamic obesity, with more regulatory and clinical trial catalysts pending. Enbridge is positioned as the defensive pick, offering a 5.2% dividend yield, 31 years of dividend growth, and about $50 billion of identified growth opportunities through 2030.

Analysis

The three names cluster into two very different trade archetypes: TMDX and RYTM are duration-sensitive growth stories where near-term disappointment can coexist with intact multi-year optionality, while ENB is effectively a bond proxy with embedded real-asset inflation hedging. The key second-order point is that both healthcare names are being punished on current-period earnings while the market is underpricing the operating leverage that comes from regulatory expansion and new product cycles; in each case, the inflection is more about revenue mix and installed-base utilization than headline EPS this quarter.

For TMDX, the selloff looks most interesting if one believes the market is extrapolating expense growth linearly while ignoring that logistics-heavy platforms often show lumpy profitability during network buildouts. The European launch and kidney program are the real swing factors: if kidneys become the third organ category, the addressable market broadens materially and the platform narrative shifts from niche device to workflow standardization. The risk is execution slippage or reimbursement friction, which would keep cash burn elevated and extend the de-rating for another 2-3 quarters.

RYTM has a cleaner catalyst stack because the next 2-6 months are packed with event risk that can re-rate the name quickly if results confirm expansion beyond the initial indication. The contrarian miss is that consensus may still be thinking in orphan-drug terms, when the addressable population is moving toward specialty-endocrine scale; that changes peak-sales assumptions and makes manufacturing, access, and payer dynamics the real bottlenecks. ENB, by contrast, should attract capital from investors rotating out of high-beta healthcare, and its utility-like cash flows become more valuable if rates stay higher for longer.

The broader opportunity is in relative-value positioning: the market is likely overpaying for near-term certainty and underpaying for pipeline and platform monetization. If the healthcare names continue to rebound on catalysts, the trade should favor owning optionality ahead of binary dates rather than chasing after approval/earnings events. ENB can serve as the defensive ballast while waiting for the growth stories to de-risk.

Key Decisions for Investors

• Initiate a 2-4 week tactical long in RYTM ahead of the next clinical readout; target a fast 10-15% upside re-rating if data are merely supportive, with a tight 7-8% stop if the market starts to discount payer or safety risk.
• Buy TMDX on weakness only after post-earnings volatility settles; structure as a staggered entry over 30-60 days because the core risk is a further multiple compression if operating expense growth remains ahead of revenue.
• Pair trade: long RYTM / short a basket of lower-catalyst healthcare names to isolate event-driven upside; this captures the higher catalyst density while reducing sector beta.
• Use ENB as a defensive long for 6-12 months if portfolio volatility is elevated; the risk/reward is modest but attractive for income-plus-total-return, especially versus stretched rate-sensitive defensives.
• For more aggressive accounts, consider call spreads in TMDX or RYTM rather than common stock; the setup is asymmetric, but the premium structure limits damage if the next catalyst disappoints.